This was discussed at length in a previous thread regarding this trial; nothing unexpected. Trial protocols (study design) need to be structured in a particular way to ensure scientific rigor, particularly given this is a new product with new clinical endpoints to be considered.
Full steam ahead.
This was discussed at length in a previous thread regarding this...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.33 |
Change
-0.120(4.90%) |
Mkt cap ! $1.608B | |||
| Open | High | Low | Value | Volume |
| $2.43 | $2.43 | $2.33 | $3.832M | 1.618M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19462 | $2.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.35 | 14948 | 5 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |